Business

Leading AI chipmaker Nvidia Corp saw its stock fall 8.5% on Thursday - the biggest drop in a month - after delivering quarterly results that were strong but failed to meet investors' sky-high expectations. The company guided for fiscal first-quarter sales of about $43 billion, slightly ahead of analysts' average estimate of $42.3 billion but below some high estimates that had reached $48 billion. The drop in share price comes after concerns that demand for Nvidia's AI chips could slow due to spending cuts by data center operators. Additional to the pressure, Nvidia warned that profit margins could be lower than estimates due to the acceleration of the rollout of its new Blackwell chip architecture. The company also faces potential challenges from U.S. tariffs that could impact futur...

Global demand for liquefied natural gas (LNG) will increase by 60% by 2040, according to Shell's LNG Outlook 2025, released today. The growth forecast is driven mainly by economic growth in Asia, industrial emissions reduction initiatives and energy requirements for artificial intelligence technologies. Industry analysts now estimate that LNG demand will reach between 630-718 million tonnes annually by 2040, an upward revision from previous estimates. This comes as global LNG trade grows by just 2 million tonnes to 407 million tonnes in 2024, marking the slowest annual growth in ten years due to limited new supply growth. "The world will need more gas for power generation, heating and cooling, industry and transport to meet growth and decarbonisation targets," said Tom Summers, seni...

Gland Pharma shares rose nearly 5 percent on February 25, its best day in 16 weeks, ahead of its investor meet during the analyst day with Emkay and BOB Capital on February 27-28. Business daily Livemint had reported in February quoting sources that Blackstone, Brookfield and Warburg Pincus were in talks to acquire a majority stake in generic injectables maker Gland Pharma. The deal between the three global private equity majors and Shanghai-based Fosun Pharma - which owns a majority stake - is expected to value Gland Pharma at around $3 billion. Gland Pharma's performance in the December quarter has been disappointing, with revenue growth in its core business being weak. The injectables company also faced challenges from its recently acquired Senexi business, which impacted its ...

Shares of drugmaker, Pfizer Ltd outperformed in an otherwise weak market. The stock of the multinational drugmaker listed on Indian exchanges rose 9% and hit an intraday high of ₹4,477 on the NSE after the company on Friday announced that it has entered into a marketing and supply agreement with Mylan Pharmaceuticals Pvt Ltd. Pfizer said it has entered into an agreement with Mylan for a period of five years to market and sell two brands Ativan and Pacitane in India. Ativan is a drug used to treat anxiety in adults and children aged 12 years and above. It also treats insomnia caused by anxiety in adults while Pacitane is indicated to treat Parkinson's disease and extrapyramidal symptoms. "Mylan has a strong presence in the central nervous system therapy space, with skilled resources ...

NHPC shares on Friday rose over 10 per cent for the third consecutive session, surging over 10 per cent following positive brokerage reports on the state-owned hydropower firm. NHPC shares rose nearly 3 per cent to hit an intraday high of Rs 82.16. This is the third consecutive day the stock is trading in the green. On Thursday, the stock gained 6.94 per cent. Over 2.57 crore shares of the stock were exchanged today, taking the total turnover to Rs 209.35 crore, as per NSE data. This sharp surge was witnessed after CLSA upgraded the stock from 'perform' to 'outperform' rating, indicating positive levers for growth. In an exclusive interview to Moneycontrol, Raj Kumar Chaudhary, chairman and managing director of the public sector undertaking (PSU), told NHPC that it will commissio...